Cell membrane-derived nanomaterials for biomedical applications

Biomaterials

Volumn 128, Issue , 2017, Pages 69-83

  Fang, Ronnie H ^a   Jiang, Yao ^a   Fang, Jean C ^a   Zhang, Liangfang ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biomimetic nanoparticle; Cell membrane; Detoxification; Drug delivery; Imaging; Immunotherapy

Indexed keywords

BIOMIMETICS; CELL MEMBRANES; CYTOLOGY; DETOXIFICATION; IMAGING TECHNIQUES; MEDICAL APPLICATIONS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; SIGNAL TRANSDUCTION;

BIOMEDICAL APPLICATIONS; BIOMIMETIC DESIGN; BIOMIMETIC NANOPARTICLES; CELLULAR MEMBRANES; COMPLEX BIOLOGICAL SYSTEMS; EMERGING TECHNOLOGIES; IMMUNOTHERAPY; NOVEL APPLICATIONS;

DRUG DELIVERY;

CARBOHYDRATE DERIVATIVE; NANOMATERIAL; NANOPARTICLE; PEPTIDE DERIVATIVE; PROTEIN DERIVATIVE;

CELL MEMBRANE; DETOXIFICATION; ENZYME THERAPY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MEMBRANE STRUCTURE; NANOMEDICINE; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; GENETIC PROCEDURES; HUMAN; MEDICAL TECHNOLOGY; METABOLISM; PROCEDURES;

ANIMALS; BIOMEDICAL TECHNOLOGY; BIOSENSING TECHNIQUES; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOMODULATION; NANOSTRUCTURES;

EID: 85014973443     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2017.02.041     Document Type: Review

References (255)

1. [1] Fang, R.H., Zhang, L., Nanoparticle-based modulation of the immune system. Annu. Rev. Chem. Biomol. Eng. 7 (2016), 305–326.
2. [2] Wang, A.Z., Langer, R., Farokhzad, O.C., Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63 (2012), 185–198.
3. [3] Fang, R.H., Kroll, A.V., Zhang, L., Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy. Small 11:41 (2015), 5483–5496.
4. [4] Fang, R.H., Luk, B.T., Hu, C.-M.J., Zhang, L., Engineered nanoparticles mimicking cell membranes for toxin neutralization. Adv. Drug Deliv. Rev. 90 (2015), 69–80.
5. [5] Dehaini, D., Fang, R.H., Zhang, L., Biomimetic strategies for targeted nanoparticle delivery. Bioeng. Transl. Med. 1:1 (2016), 30–46.
6. [6] Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C., Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5:4 (2008), 505–515.
7. [7] Hu, C.-M.J., Fang, R.H., Zhang, L., Erythrocyte-inspired delivery systems. Adv. Healthc. Mater. 1:5 (2012), 537–547.
8. [8] Fang, R.H., Hu, C.-M.J., Zhang, L., Nanoparticles disguised as red blood cells to evade the immune system. Expert Opin. Biol. Ther. 12:4 (2012), 385–389.
9. [9] Molek, P., Strukelj, B., Bratkovic, T., Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules 16:1 (2011), 857–887.
10. [10] Shan, Y., Wang, H., The structure and function of cell membranes examined by atomic force microscopy and single-molecule force spectroscopy. Chem. Soc. Rev. 44:11 (2015), 3617–3638.
11. [11] Berg, J.M., Tymoczko, J.L., Stryer, L., Carbohydrates Can Be Attached to Proteins to Form Glycoproteins, W H Freeman. 2002.
12. [12] Varki, A., Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 3:2 (1993), 97–130.
13. [13] Spiess, M., The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 29:43 (1990), 10009–10018.
14. [14] Cho, C.S., Cho, K.Y., Park, I.K., Kim, S.H., Sasagawa, T., Uchiyama, M., Akaike, T., Receptor-mediated delivery of all trans-retinoic acid to hepatocyte using poly(L-lactic acid) nanoparticles coated with galactose-carrying polystyrene. J. Control. Release 77:1–2 (2001), 7–15.
15. [15] Lai, C.-H., Lin, C.-Y., Wu, H.-T., Chan, H.-S., Chuang, Y.-J., Chen, C.-T., Lin, C.-C., Galactose encapsulated multifunctional nanoparticle for HepG2 cell internalization. Adv. Funct. Mater. 20:22 (2010), 3948–3958.
16. [16] Kawakami, S., Wong, J., Sato, A., Hattori, Y., Yamashita, F., Hashida, M., Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochim. Biophys. Acta 1524:2–3 (2000), 258–265.
17. [17] Bergen, J.M., von Recum, H.A., Goodman, T.T., Massey, A.P., Pun, S.H., Gold nanoparticles as a versatile platform for optimizing physicochemical parameters for targeted drug delivery. Macromol. Biosci. 6:7 (2006), 506–516.
18. [18] Zhang, J., Garrison, J.C., Poluektova, L.Y., Bronich, T.K., Osna, N.A., Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics. Biomaterials 70 (2015), 37–47.
19. [19] Kim, T.H., Park, I.K., Nah, J.W., Choi, Y.J., Cho, C.S., Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials 25:17 (2004), 3783–3792.
20. [20] Sato, A., Takagi, M., Shimamoto, A., Kawakami, S., Hashida, M., Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28:7 (2007), 1434–1442.
21. [21] El-Serag, H.B., Hepatocellular carcinoma. N. Engl. J. Med. 365:12 (2011), 1118–1127.
22. [22] Jeong, Y.-I., Seo, S.-J., Park, I.-K., Lee, H.-C., Kang, I.-C., Akaike, T., Cho, C.-S., Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(γ-benzyl l-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int. J. Pharm. 296:1–2 (2005), 151–161.
23. [23] Quan, S., Wang, Y., Zhou, A., Kumar, P., Narain, R., Galactose-based thermosensitive nanogels for targeted drug delivery of iodoazomycin arabinofuranoside (IAZA) for theranostic management of hypoxic hepatocellular carcinoma. Biomacromolecules 16:7 (2015), 1978–1986.
24. [24] Babiuch, K., Dag, A., Zhao, J., Lu, H., Stenzel, M.H., Carbohydrate-specific uptake of fucosylated polymeric micelles by different cancer cell lines. Biomacromolecules 16:7 (2015), 1948–1957.
25. [25] Yoshida, M., Takimoto, R., Murase, K., Sato, Y., Hirakawa, M., Tamura, F., Sato, T., Iyama, S., Osuga, T., Miyanishi, K., Takada, K., Hayashi, T., Kobune, M., Kato, J., Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach. PLoS One, 7(7), 2012, e39545.
26. [26] Yeh, Y.-C., Kim, S.T., Tang, R., Yan, B., Rotello, V.M., Insulin-based regulation of glucose-functionalized nanoparticle uptake in muscle cells. J. Mater. Chem. B Mater. Biol. Med. 2 (2014), 4610–4614.
27. [27] Gromnicova, R., Davies, H.A., Sreekanthreddy, P., Romero, I.A., Lund, T., Roitt, I.M., Phillips, J.B., Male, D.K., Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro. PLoS One, 8(12), 2013, e81043.
28. [28] Tosi, G., Vergoni, A.V., Ruozi, B., Bondioli, L., Badiali, L., Rivasi, F., Costantino, L., Forni, F., Vandelli, M.A., Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J. Control. Release 145:1 (2010), 49–57.
29. [29] Marradi, M., Martín-Lomas, M., Penadés, S., Glyconanoparticles: polyvalent tools to study carbohydrate-based interactions. Horton, Derek, (eds.) Advances in Carbohydrate Chemistry and Biochemistry, 2010, Academic Press, 211–290.
30. [30] Valero, E., Tambalo, S., Marzola, P., Ortega-Muñoz, M., López-Jaramillo, F.J., Santoyo-González, F., de Dios López, J., Delgado, J.J., Calvino, J.J., Cuesta, R., Domínguez-Vera, J.M., Gálvez, N., Magnetic nanoparticles-templated assembly of protein subunits: a new platform for carbohydrate-based MRI nanoprobes. J. Am. Chem. Soc. 133:13 (2011), 4889–4895.
31. [31] Horák, D., Babič, M., Jendelová, P., Herynek, V., Trchová, M., Pientka, Z., Pollert, E., Hájek, M., Syková, E., d-Mannose-modified iron oxide nanoparticles for stem cell labeling. Bioconjug. Chem. 18:3 (2007), 635–644.
32. [32] Yoo, M.K., Kim, I.Y., Kim, E.M., Jeong, H.-J., Lee, C.-M., Jeong, Y.Y., Akaike, T., Cho, C.S., Superparamagnetic iron oxide nanoparticles coated with galactose-carrying polymer for hepatocyte targeting. J. Biomed. Biotechnol., 2007(10), 2007, 94740.
33. [33] Zheng, H., Mortensen, L.J., DeLouise, L.A., Thiol antioxidant-functionalized CdSe/ZnS quantum dots: synthesis, characterization, cytotoxicity. J. Biomed. Nanotechnol. 9:3 (2013), 382–392.
34. [34] Ohyanagi, T., Nagahori, N., Shimawaki, K., Hinou, H., Yamashita, T., Sasaki, A., Jin, T., Iwanaga, T., Kinjo, M., Nishimura, S.-I., Importance of sialic acid residues illuminated by live animal imaging using phosphorylcholine self-assembled monolayer-coated quantum dots. J. Am. Chem. Soc. 133:32 (2011), 12507–12517.
35. [35] Higuchi, Y., Oka, M., Kawakami, S., Hashida, M., Mannosylated semiconductor quantum dots for the labeling of macrophages. J. Control. Release 125:2 (2008), 131–136.
36. [36] Kikkeri, R., Lepenies, B., Adibekian, A., Laurino, P., Seeberger, P.H., In vitro imaging and in vivo liver targeting with carbohydrate capped quantum dots. J. Am. Chem. Soc. 131:6 (2009), 2110–2112.
37. [37] Irache, J.M., Salman, H.H., Gamazo, C., Espuelas, S., Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5:6 (2008), 703–724.
38. [38] Linehan, S.A., Martínez-Pomares, L., Stahl, P.D., Gordon, S., Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: in situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells. J. Exp. Med. 189:12 (1999), 1961–1972.
39. [39] Sallusto, F., Cella, M., Danieli, C., Lanzavecchia, A., Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:2 (1995), 389–400.
40. [40] Galili, U., Clark, M.R., Shohet, S.B., Buehler, J., Macher, B.A., Evolutionary relationship between the natural anti-Gal antibody and the Galα1→3Gal epitope in primates. Proc. Natl. Acad. Sci. U. S. A 84:5 (1987), 1369–1373.
41. [41] Phanse, Y., Carrillo-Conde, B.R., Ramer-Tait, A.E., Broderick, S., Kong, C.S., Rajan, K., Flick, R., Mandell, R.B., Narasimhan, B., Wannemuehler, M.J., A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms. Sci. Rep., 4, 2014, 3775.
42. [42] Xu, Z., Ramishetti, S., Tseng, Y.-C., Guo, S., Wang, Y., Huang, L., Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J. Control. Release 172:1 (2013), 259–265.
43. [43] Kim, T.H., Jin, H., Kim, H.W., Cho, M.H., Cho, C.S., Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol. Cancer Ther. 5:7 (2006), 1723–1732.
44. [44] Zhu, S., Niu, M., O'Mary, H., Cui, Z., Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol. Pharm. 10:9 (2013), 3525–3530.
45. [45] Spence, S., Greene, M.K., Fay, F., Hams, E., Saunders, S.P., Hamid, U., Fitzgerald, M., Beck, J., Bains, B.K., Smyth, P., Themistou, E., Small, D.M., Schmid, D., O'Kane, C.M., Fitzgerald, D.C., Abdelghany, S.M., Johnston, J.A., Fallon, P.G., Burrows, J.F., McAuley, D.F., Kissenpfennig, A., Scott, C.J., Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation. Sci. Transl. Med., 7(303), 2015 303ra140.
46. [46] Wang, X., Ramström, O., Yan, M., Quantitative analysis of multivalent ligand presentation on gold glyconanoparticles and the impact on lectin binding. Anal. Chem. 82:21 (2010), 9082–9089.
47. [47] Lyu, Y.-K., Lim, K.-R., Lee, B.Y., Kim, K.S., Lee, W.-Y., Microgravimetric lectinbiosensor based on signal amplification using carbohydrate-stabilized gold nanoparticles. Chem. Commun. 39 (2008), 4771–4773.
48. [48] Bellapadrona, G., Tesler, A.B., Grünstein, D., Hossain, L.H., Kikkeri, R., Seeberger, P.H., Vaskevich, A., Rubinstein, I., Optimization of localized surface plasmon resonance transducers for studying carbohydrate–protein interactions. Anal. Chem. 84:1 (2012), 232–240.
49. [49] Hone, D.C., Haines, A.H., Russell, D.A., Rapid, quantitative colorimetric detection of a lectin using mannose-stabilized gold nanoparticles. Langmuir 19:17 (2003), 7141–7144.
50. [50] Lee, C., Gaston, M.A., Weiss, A.A., Zhang, P., Colorimetric viral detection based on sialic acid stabilized goldnanoparticles. Biosens. Bioelectron. 42 (2013), 236–241.
51. [51] Otsuka, H., Akiyama, Y., Nagasaki, Y., Kataoka, K., Quantitative and reversible lectin-induced association of gold nanoparticles modified with α-lactosyl-ω-mercapto-poly(ethylene glycol). J. Am. Chem. Soc. 123:34 (2001), 8226–8230.
52. [52] Vedala, H., Chen, Y., Cecioni, S., Imberty, A., Vidal, S., Star, A., Nanoelectronic detection of lectin–carbohydrate interactions using carbon nanotubes. Nano Lett. 11:1 (2011), 170–175.
53. [53] Chen, Y., Vedala, H., Kotchey, G.P., Audfray, A., Cecioni, S., Imberty, A., Vidal, S., Star, A., Electronic detection of lectins using carbohydrate-functionalized nanostructures: graphene versus carbon nanotubes. ACS Nano 6:1 (2012), 760–770.
54. [54] El-Boubbou, K., Gruden, C., Huang, X., Magnetic glyco-nanoparticles: a unique tool for rapid pathogen detection, decontamination, and strain differentiation. J. Am. Chem. Soc. 129:44 (2007), 13392–13393.
55. [55] El-Boubbou, K., Zhu, D.C., Vasileiou, C., Borhan, B., Prosperi, D., Li, W., Huang, X., Magnetic glyco-nanoparticles: a tool to detect, differentiate, and unlock the glyco-codes of cancer via magnetic resonance imaging. J. Am. Chem. Soc. 132:12 (2010), 4490–4499.
56. [56] Lin, Y.-H., Tsai, S.-C., Lai, C.-H., Lee, C.-H., He, Z.S., Tseng, G.-C., Genipin-cross-linked fucose–chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials 34:18 (2013), 4466–4479.
57. [57] Papp, I., Sieben, C., Ludwig, K., Roskamp, M., Böttcher, C., Schlecht, S., Herrmann, A., Haag, R., Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles. Small 6:24 (2010), 2900–2906.
58. [58] Rodriguez, P.L., Harada, T., Christian, D.A., Pantano, D.A., Tsai, R.K., Discher, D.E., Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339:6122 (2013), 971–975.
59. [59] Oldenborg, P.A., Zheleznyak, A., Fang, Y.F., Lagenaur, C.F., Gresham, H.D., Lindberg, F.P., Role of CD47 as a marker of self on red blood cells. Science 288:5473 (2000), 2051–2054.
60. [60] Yang, Q., Lai, S.K., Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7:5 (2015), 655–677.
61. [61] Tsai, R.K., Rodriguez, P.L., Discher, D.E., Self inhibition of phagocytosis: the affinity of “marker of self” CD47 for SIRPα dictates potency of inhibition but only at low expression levels. Blood Cells Mol. Dis. 45:1 (2010), 67–74.
62. [62] Olive, C., Clair, T., Yarwood, P., Good, M.F., Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 20:21–22 (2002), 2816–2825.
63. [63] Olive, C., Batzloff, M.R., Horváth, A., Wong, A., Clair, T., Yarwood, P., Toth, I., Good, M.F., A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect. Immun. 70:5 (2002), 2734–2738.
64. [64] Hayman, W.A., Brandt, E.R., Relf, W.A., Cooper, J., Saul, A., Good, M.F., Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int. Immunol. 9:11 (1997), 1723–1733.
65. [65] Skwarczynski, M., Zaman, M., Urbani, C.N., Lin, I.-C., Jia, Z., Batzloff, M.R., Good, M.F., Monteiro, M.J., Toth, I., Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew. Chem. Int. Ed. Engl. 49:33 (2010), 5742–5745.
66. [66] Skwarczynski, M., Parhiz, B.H., Soltani, F., Srinivasan, S., Kamaruzaman, K.A., Lin, I.-C., Toth, I., Lipid peptide core nanoparticles as multivalent vaccine candidates against Streptococcus pyogenes. Aust. J. Chem. 65:1 (2012), 35–39.
67. [67] Rennermalm, A., Li, Y.H., Bohaufs, L., Jarstrand, C., Brauner, A., Brennan, F.R., Flock, J.I., Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 19:25–26 (2001), 3376–3383.
68. [68] Kaba, S.A., Brando, C., Guo, Q., Mittelholzer, C., Raman, S., Tropel, D., Aebi, U., Burkhard, P., Lanar, D.E., A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol. 183:11 (2009), 7268–7277.
69. [69] Kampen, K.R., Membrane proteins: the key players of a cancer cell. J. Membr. Biol. 242:2 (2011), 69–74.
70. [70] Cheever, M.A., Allison, J.P., Ferris, A.S., Finn, O.J., Hastings, B.M., Hecht, T.T., Mellman, I., Prindiville, S.A., Viner, J.L., Weiner, L.M., Matrisian, L.M., The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15:17 (2009), 5323–5337.
71. [71] Newman, K.D., Sosnowski, D.L., Kwon, G.S., Samuel, J., Delivery of MUC1 mucin peptide by poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J. Pharm. Sci. 87:11 (1998), 1421–1427.
72. [72] Diwan, M., Elamanchili, P., Lane, H., Gainer, A., Samuel, J., Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J. Drug Target 11:8–10 (2003), 495–507.
73. [73] Cai, H., Degliangeli, F., Palitzsch, B., Gerlitzki, B., Kunz, H., Schmitt, E., Fiammengo, R., Westerlind, U., Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein. Bioorg. Med. Chem. 24:5 (2016), 1132–1135.
74. [74] Hartmann, S., Nuhn, L., Palitzsch, B., Glaffig, M., Stergiou, N., Gerlitzki, B., Schmitt, E., Kunz, H., Zentel, R., CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines. Adv. Healthc. Mater. 4:4 (2015), 522–527.
75. [75] Jalali, S.A., Sankian, M., Tavakkol-Afshari, J., Jaafari, M.R., Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD nanoparticles. Nanomedicine 8:5 (2012), 692–701.
76. [76] Lin, A.Y., Lunsford, J., Bear, A.S., Young, J.K., Eckels, P., Luo, L., Foster, A.E., Drezek, R.A., High-density sub-100-nm peptide–gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro. Nanoscale Res. Lett., 8(1), 2013, 72.
77. + T-cell responses in melanoma patients. Eur. J. Immunol. 42:11 (2012), 3049–3061.
78. [78] Getts, D.R., Martin, A.J., McCarthy, D.P., Terry, R.L., Hunter, Z.N., Yap, W.T., Getts, M.T., Pleiss, M., Luo, X., King, N.J.C., Shea, L.D., Miller, S.D., Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat. Biotechnol. 30:12 (2012), 1217–1224.
79. [79] Hunter, Z., McCarthy, D.P., Yap, W.T., Harp, C.T., Getts, D.R., Shea, L.D., Miller, S.D., A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 8:3 (2014), 2148–2160.
80. [80] Wang, Q., Smith, C., Molecular biology of the cell (fifth ed.). Biosci. Educ. 11:1 (2008), 1–2.
81. [81] Jebali, A., Nayeri, E.K., Roohana, S., Aghaei, S., Ghaffari, M., Daliri, K., Fuente, G., Nano-carbohydrates: synthesis and application in genetics, biotechnology, and Medicine. Adv. Colloid Interface Sci., 2016, 10.1016/j.cis.2016.11.002.
82. [82] Johannssen, T., Lepenies, B., Glycan-based cell targeting to modulate immune responses. Trends Biotechnol., 2016, 10.1016/j.tibtech.2016.10.002.
83. [83] Sackstein, R., Merzaban, J.S., Cain, D.W., Dagia, N.M., Spencer, J.A., Lin, C.P., Wohlgemuth, R., Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 14:2 (2008), 181–187.
84. [84] Eniola, A.O., Rodgers, S.D., Hammer, D.A., Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes. Biomaterials 23:10 (2002), 2167–2177.
85. [85] Eniola, A.O.A.O., Hammer, D.A.D.A., Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes II: effect of degradation on targeting activity. Biomaterials 26:6 (2005), 661–670.
86. [86] van Kasteren, S.I., Campbell, S.J., Serres, S., Anthony, D.C., Sibson, N.R., Davis, B.G., Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease. Proc. Natl. Acad. Sci. U. S. A 106:1 (2009), 18–23.
87. [87] Farr, T.D., Lai, C.-H., Grünstein, D., Orts-Gil, G., Wang, C.-C., Boehm-Sturm, P., Seeberger, P.H., Harms, C., Imaging early endothelial inflammation following stroke by core shell silica superparamagnetic glyconanoparticles that target selectin. Nano Lett. 14:4 (2014), 2130–2134.
88. [88] Cruz, L.J., Tacken, P.J., Pots, J.M., Torensma, R., Buschow, S.I., Figdor, C.G., Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 33:16 (2012), 4229–4239.
89. [89] Büll, C., Heise, T., Adema, G.J., Boltje, T.J., Sialic acid mimetics to target the sialic acid–Siglec axis. Trends Biochem. Sci. 41:6 (2016), 519–531.
90. [90] Unger, W.W.J., van Beelen, A.J., Bruijns, S.C., Joshi, M., Fehres, C.M., van Bloois, L., Verstege, M.I., Ambrosini, M., Kalay, H., Nazmi, K., Bolscher, J.G., Hooijberg, E., de Gruijl, T.D., Storm, G., van Kooyk, Y., Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J. Control. Release 160:1 (2012), 88–95.
91. [91] Arosio, D., Chiodo, F., Reina, J.J., Marelli, M., Penadés, S., van Kooyk, Y., Garcia-Vallejo, J.J., Bernardi, A., Effective targeting of DC-SIGN by α-fucosylamide functionalized gold nanoparticles. Bioconjug. Chem. 25:12 (2014), 2244–2251.
92. [92] Macauley, M.S., Pfrengle, F., Rademacher, C., Nycholat, C.M., Gale, A.J., von Drygalski, A., Paulson, J.C., Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J. Clin. Invest. 123:7 (2013), 3074–3083.
93. [93] Blattes, E., Vercellone, A., Eutamène, H., Turrin, C.-O., Théodorou, V., Majoral, J.-P., Caminade, A.-M., Prandi, J., Nigou, J., Puzo, G., Mannodendrimers prevent acute lung inflammation by inhibiting neutrophil recruitment. Proc. Natl. Acad. Sci. U. S. A 110:22 (2013), 8795–8800.
94. [94] Park, S., Kim, G.-H., Park, S.-H., Pai, J., Rathwell, D., Park, J.-Y., Kang, Y.-S., Shin, I., Probing cell-surface carbohydrate binding proteins with dual-modal glycan-conjugated nanoparticles. J. Am. Chem. Soc. 137:18 (2015), 5961–5968.
95. [95] Zheng, L., Wei, J., Lv, X., Bi, Y., Wu, P., Zhang, Z., Wang, P., Liu, R., Jiang, J., Cong, H., Liang, J., Chen, W., Cao, H., Liu, W., Gao, G.F., Du, Y., Jiang, X., Li, X., Detection and differentiation of influenza viruses with glycan-functionalized gold nanoparticles. Biosens. Bioelectron. 91 (2016), 46–52.
96. [96] de la Fuente, J.M., Barrientos, A.G., Rojas, T.C., Rojo, J., Cañada, J., Fernández, A., Penadés, S., Gold glyconanoparticles as water-soluble polyvalent models to study carbohydrate interactions. Angew. Chem. Int. Ed. Engl. 113:12 (2001), 2317–2321.
97. [97] Rojo, J., Díaz, V., de la Fuente, J.M., Segura, I., Barrientos, A.G., Riese, H.H., Bernad, A., Penadés, S., Gold glyconanoparticles as new tools in antiadhesive therapy. Chembiochem 5:3 (2004), 291–297.
98. [98] Garcia-Vallejo, J.J., Koning, N., Ambrosini, M., Kalay, H., Vuist, I., Sarrami-Forooshani, R., Geijtenbeek, T.B.H., van Kooyk, Y., Glycodendrimers prevent HIV transmission via DC-SIGN on dendritic cells. Int. Immunol. 25:4 (2013), 221–233.
99. [99] Sattin, S., Bernardi, A., Glycoconjugates and glycomimetics as microbial anti-adhesives. Trends Biotechnol. 34:6 (2016), 483–495.
100. [100] Kulkarni, A.A., Fuller, C., Korman, H., Weiss, A.A., Iyer, S.S., Glycan encapsulated gold nanoparticles selectively inhibit shiga toxins 1 and 2. Bioconjug. Chem. 21:8 (2010), 1486–1493.
101. [101] Moulari, B., Béduneau, A., Pellequer, Y., Lamprecht, A., Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J. Control. Release 188 (2014), 9–17.
102. [102] Feugang, J., Liao, S., Crenshaw, M., Clemente, H., Willard, S., et al. Lectin-functionalized magnetic iron oxide nanoparticles for reproductive improvement. JFIV Reprod. Med. Genet. 3:145 (2015), 17–19.
103. [103] Kona, S., Dong, J.-F., Liu, Y., Tan, J., Nguyen, K.T., Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. Int. J. Pharm. 423:2 (2012), 516–524.
104. [104] Perica, K., De León Medero, A., Durai, M., Chiu, Y.L., Bieler, J.G., Sibener, L., Niemöller, M., Assenmacher, M., Richter, A., Edidin, M., Oelke, M., Schneck, J., Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine 10:1 (2014), 119–129.
105. [105] Perica, K., Tu, A., Richter, A., Bieler, J.G., Edidin, M., Schneck, J.P., Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. ACS Nano 8:3 (2014), 2252–2260.
106. [106] Perica, K., Bieler, J.G., Schütz, C., Varela, J.C., Douglass, J., Skora, A., Chiu, Y.L., Oelke, M., Kinzler, K., Zhou, S., Vogelstein, B., Schneck, J.P., Enrichment and expansion with nanoscale artificial antigen presenting cells for adoptive immunotherapy. ACS Nano 9:7 (2015), 6861–6871.
107. [107] Meyer, R.A., Sunshine, J.C., Perica, K., Kosmides, A.K., Aje, K., Schneck, J.P., Green, J.J., Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small 11:13 (2015), 1519–1525.
108. [108] Clemente-Casares, X., Blanco, J., Ambalavanan, P., Yamanouchi, J., Singha, S., Fandos, C., Tsai, S., Wang, J., Garabatos, N., Izquierdo, C., Agrawal, S., Keough, M.B., Yong, V.W., James, E., Moore, A., Yang, Y., Stratmann, T., Serra, P., Santamaria, P., Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 530:7591 (2016), 434–440.
109. [109] Bookbinder, L.H., Hofer, A., Haller, M.F., Zepeda, M.L., Keller, G.-A., Lim, J.E., Edgington, T.S., Shepard, H.M., Patton, J.S., Frost, G.I., A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control. Release 114:2 (2006), 230–241.
110. [110] Eikenes, L., Tari, M., Tufto, I., Bruland, O.S., de Lange Davies, C., Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 93:1 (2005), 81–88.
111. [111] Muckenschnabel, I., Bernhardt, G., Spruss, T., Buschauer, A., Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice. Cancer Chemother. Pharmacol. 38:1 (1996), 88–94.
112. [112] Scodeller, P., Catalano, P.N., Salguero, N., Duran, H., Wolosiuk, A., Soler-Illia, G.J.A.A., Hyaluronan degrading silica nanoparticles for skin cancer therapy. Nanoscale 5:20 (2013), 9690–9698.
113. [113] Zhou, H., Fan, Z., Lemons, P.K., Cheng, H., A facile approach to functionalize cell membrane-coated nanoparticles. Theranostics 6:7 (2016), 1012–1022.
114. [114] Zhou, H., Fan, Z., Deng, J., Lemons, P.K., Arhontoulis, D.C., Bowne, W.B., Cheng, H., Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy. Nano Lett. 16:5 (2016), 3268–3277.
115. [115] Colombo, M., Raposo, G., Théry, C., Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30 (2014), 255–289.
116. [116] Xu, W., Yang, Z., Lu, N., From pathogenesis to clinical application: insights into exosomes as transfer vectors in cancer. J. Exp. Clin. Cancer Res., 35(1), 2016, 156.
117. [117] Dorayappan, K.D.P., Wallbillich, J.J., Cohn, D.E., Selvendiran, K., The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol. Oncol. 142:1 (2016), 199–205.
118. [118] Zhang, X., Pei, Z., Chen, J., Ji, C., Xu, J., Zhang, X., Wang, J., Exosomes for immunoregulation and therapeutic intervention in cancer. J. Cancer 7:9 (2016), 1081–1087.
119. [119] Olsen, I., Amano, A., Outer membrane vesicles - offensive weapons or good Samaritans?. J. Oral Microbiol., 7, 2015, 27468.
120. [120] Schwechheimer, C., Kuehn, M.J., Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat. Rev. Microbiol. 13:10 (2015), 605–619.
121. [121] Andaloussi, S.E.L., Mäger, I., Breakefield, X.O., Wood, M.J.A., Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12:5 (2013), 347–357.
122. [122] Ha, D., Yang, N., Nadithe, V., Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm. Sin. B 6:4 (2016), 287–296.
123. [123] Johnsen, K.B., Gudbergsson, J.M., Skov, M.N., Pilgaard, L., Moos, T., Duroux, M., A comprehensive overview of exosomes as drug delivery vehicles — Endogenous nanocarriers for targeted cancer therapy. BBA Rev. Cancer 1846:1 (2014), 75–87.
124. [124] Ren, J., He, W., Zheng, L., Duan, H., From structures to functions: insights into exosomes as promising drug delivery vehicles. Biomater. Sci. 4:6 (2016), 910–921.
125. [125] Wahlgren, J., De, T., Karlson, L., Brisslert, M., Vaziri Sani, F., Telemo, E., Sunnerhagen, P., Valadi, H., Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res., 40(17), 2012, e130.
126. [126] Yeo, R.W.Y., Lai, R.C., Zhang, B., Tan, S.S., Yin, Y., Teh, B.J., Lim, S.K., Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 65:3 (2013), 336–341.
127. [127] Hoshino, A., Costa-Silva, B., Shen, T.-L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., Singh, S., Williams, C., Soplop, N., Uryu, K., Pharmer, L., King, T., Bojmar, L., Davies, A.E., Ararso, Y., Zhang, T., Zhang, H., Hernandez, J., Weiss, J.M., Dumont-Cole, V.D., Kramer, K., Wexler, L.H., Narendran, A., Schwartz, G.K., Healey, J.H., Sandstrom, P., Labori, K.J., Kure, E.H., Grandgenett, P.M., Hollingsworth, M.A., de Sousa, M., Kaur, S., Jain, M., Mallya, K., Batra, S.K., Jarnagin, W.R., Brady, M.S., Fodstad, O., Muller, V., Pantel, K., Minn, A.J., Bissell, M.J., Garcia, B.A., Kang, Y., Rajasekhar, V.K., Ghajar, C.M., Matei, I., Peinado, H., Bromberg, J., Lyden, D., Tumour exosome integrins determine organotropic metastasis. Nature 527:7578 (2015), 329–335.
128. [128] Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., Gotoh, N., Kuroda, M., Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21:1 (2013), 185–191.
129. [129] Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G.J., Wei, J., Nie, G., A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35:7 (2014), 2383–2390.
130. [130] Yang, T., Martin, P., Fogarty, B., Brown, A., Schurman, K., Phipps, R., Yin, V.P., Lockman, P., Bai, S., Exosome delivered anticancer drugs across the blood–brain barrier for brain cancer therapy in Danio rerio. Pharm. Res. 32:6 (2015), 2003–2014.
131. [131] Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., Wood, M.J.A., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29:4 (2011), 341–345.
132. [132] Haney, M.J., Klyachko, N.L., Zhao, Y., Gupta, R., Plotnikova, E.G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A.V., Batrakova, E.V., Exosomes as drug delivery vehicles for Parkinson's disease therapy. J. Control. Release 207 (2015), 18–30.
133. [133] Pascucci, L., Coccè, V., Bonomi, A., Ami, D., Ceccarelli, P., Ciusani, E., Viganò, L., Locatelli, A., Sisto, F., Doglia, S.M., Parati, E., Bernardo, M.E., Muraca, M., Alessandri, G., Bondiolotti, G., Pessina, A., Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J. Control. Release 192 (2014), 262–270.
134. [134] Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., Barnes, S., Grizzle, W., Miller, D., Zhang, H.-G., A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 18:9 (2010), 1606–1614.
135. [135] Xin, H., Li, Y., Cui, Y., Yang, J.J., Zhang, Z.G., Chopp, M., Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J. Cereb. Blood Flow. Metab. 33:11 (2013), 1711–1715.
136. [136] Zhang, Y., Chopp, M., Meng, Y., Katakowski, M., Xin, H., Mahmood, A., Xiong, Y., Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J. Neurosurg. 122:4 (2015), 856–867.
137. [137] Jang, S.C., Kim, O.Y., Yoon, C.M., Choi, D.-S., Roh, T.-Y., Park, J., Nilsson, J., Lötvall, J., Kim, Y.-K., Gho, Y.S., Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7:9 (2013), 7698–7710.
138. [138] Lejeune, A., Moorjani, M., Gicquaud, C., Lacroix, J., Poyet, P., Gaudreault, R., Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res. 14:3A (1994), 915–919.
139. [139] Lejeune, A., Poyet, P., Gaudreault, R.C., Gicquaud, C., Nanoerythrosomes, a new derivative of erythrocyte ghost: III. Is phagocytosis involved in the mechanism of action?. Anticancer Res. 17:5A (1997), 3599–3603.
140. [140] Moorjani, M., Lejeune, A., Gicquaud, C., Lacroix, J., Poyet, P., Gaudreault, R.C., Nanoerythrosomes, a new derivative of erythrocyte ghost: II. Identification of the mechanism of action. Anticancer Res. 16:5A (1996), 2831–2836.
141. [141] Désilets, J., Lejeune, A., Mercer, J., Gicquaud, C., Nanoerythrosomes, a new derivative of erythrocyte ghost: IV. Fate of reinjected nanoerythrosomes. Anticancer Res. 21:3B (2001), 1741–1747.
142. [142] Bahmani, B., Bacon, D., Anvari, B., Erythrocyte-derived photo-theranostic agents: hybrid nano-vesicles containing indocyanine green for near infrared imaging and therapeutic applications. Sci. Rep., 3, 2013, 2180.
143. [143] Gupta, N., Patel, B., Ahsan, F., Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization. Pharm. Res. 31:6 (2014), 1553–1565.
144. [144] Hsieh, C.-C., Kang, S.-T., Lin, Y.-H., Ho, Y.-J., Wang, C.-H., Yeh, C.-K., Chang, C.-W., Biomimetic acoustically-responsive vesicles for theranostic applications. Theranostics 5:11 (2015), 1264–1274.
145. [145] Mac, J.T., Nuñez, V., Burns, J.M., Guerrero, Y.A., Vullev, V.I., Anvari, B., Erythrocyte-derived nano-probes functionalized with antibodies for targeted near infrared fluorescence imaging of cancer cells. Biomed. Opt. Express 7:4 (2016), 1311–1322.
146. [146] Toledano Furman, N.E., Lupu-Haber, Y., Bronshtein, T., Kaneti, L., Letko, N., Weinstein, E., Baruch, L., Machluf, M., Reconstructed stem cell nanoghosts: a natural tumor targeting platform. Nano Lett. 13:7 (2013), 3248–3255.
147. [147] Kaneti, L., Bronshtein, T., Malkah Dayan, N., Kovregina, I., Letko Khait, N., Lupu-Haber, Y., Fliman, M., Schoen, B.W., Kaneti, G., Machluf, M., Nanoghosts as a novel natural nonviral gene delivery platform safely targeting multiple cancers. Nano Lett. 16:3 (2016), 1574–1582.
148. [148] Gao, J., Chu, D., Wang, Z., Cell membrane-formed nanovesicles for disease-targeted delivery. J. Control. Release 224 (2016), 208–216.
149. [149] Peng, L.-H., Zhang, Y.-H., Han, L.-J., Zhang, C.-Z., Wu, J.-H., Wang, X.-R., Gao, J.-Q., Mao, Z.-W., Cell membrane capsules for encapsulation of chemotherapeutic and cancer cell targeting in vivo. ACS Appl. Mater. Interfaces 7:33 (2015), 18628–18637.
150. [150] Molinaro, R., Corbo, C., Martinez, J.O., Taraballi, F., Evangelopoulos, M., Minardi, S., Yazdi, I.K., Zhao, P., De Rosa, E., Sherman, M.B., De Vita, A., Toledano Furman, N.E., Wang, X., Parodi, A., Tasciotti, E., Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat. Mater. 15:9 (2016), 1037–1046.
151. [151] Kim, S.-H., Kim, K.-S., Lee, S.-R., Kim, E., Kim, M.-S., Lee, E.-Y., Gho, Y.S., Kim, J.-W., Bishop, R.E., Chang, K.-T., Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim. Biophys. Acta 1788:10 (2009), 2150–2159.
152. [152] Kim, J.-Y., Doody, A.M., Chen, D.J., Cremona, G.H., Shuler, M.L., Putnam, D., DeLisa, M.P., Engineered bacterial outer membrane vesicles with enhanced functionality. J. Mol. Biol. 380:1 (2008), 51–66.
153. [153] Gujrati, V., Kim, S., Kim, S.-H., Min, J.J., Choy, H.E., Kim, S.C., Jon, S., Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano 8:2 (2014), 1525–1537.
154. [154] Alves, N.J., Turner, K.B., Medintz, I.L., Walper, S.A., Emerging therapeutic delivery capabilities and challenges utilizing enzyme/protein packaged bacterial vesicles. Ther. Deliv. 6:7 (2015), 873–887.
155. [155] Hao, S., Moyana, T., Xiang, J., Review: Cancer immunotherapy by exosome-based vaccines. Cancer Biother. Radiopharm. 22:5 (2007), 692–703.
156. [156] Tan, A., De La Peña, H., Seifalian, A.M., The application of exosomes as a nanoscale cancer vaccine. Int. J. Nanomed. 5 (2010), 889–900.
157. [157] Gu, X., Erb, U., Büchler, M.W., Zöller, M., Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int. J. Cancer 136:4 (2015), E74–E84.
158. [158] Kunigelis, K.E., Graner, M.W., The dichotomy of tumor exosomes (TEX) in cancer immunity: is it all in the conTEXt?. Vaccin. (Basel) 3:4 (2015), 1019–1051.
159. [159] Chen, W., Wang, J., Shao, C., Liu, S., Yu, Y., Wang, Q., Cao, X., Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur. J. Immunol. 36:6 (2006), 1598–1607.
160. [160] Dai, S., Wan, T., Wang, B., Zhou, X., Xiu, F., Chen, T., Wu, Y., Cao, X., More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin. Cancer Res. 11:20 (2005), 7554–7563.
161. [161] Cho, J.-A., Lee, Y.-S., Kim, S.-H., Ko, J.-K., Kim, C.-W., MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett. 275:2 (2009), 256–265.
162. [162] Xie, Y., Bai, O., Zhang, H., Yuan, J., Zong, S., Chibbar, R., Slattery, K., Qureshi, M., Wei, Y., Deng, Y., Xiang, J., Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J. Cell. Mol. Med. 14:11 (2010), 2655–2666.
163. [163] Wang, J., Wang, L., Lin, Z., Tao, L., Chen, M., More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells. Mol. Med. Rep. 9:1 (2014), 125–131.
164. [164] Li, W., Mu, D., Tian, F., Hu, Y., Jiang, T., Han, Y., Chen, J., Han, G., Li, X., Exosomes derived from Rab27a-overexpressing tumor cells elicit efficient induction of antitumor immunity. Mol. Med. Rep. 8:6 (2013), 1876–1882.
165. [165] Hao, S., Bai, O., Li, F., Yuan, J., Laferte, S., Xiang, J., Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 120:1 (2007), 90–102.
166. [166] Hao, S., Bai, O., Yuan, J., Qureshi, M., Xiang, J., Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell. Mol. Immunol. 3:3 (2006), 205–211.
167. [167] André, F., Chaput, N., Schartz, N.E.C., Flament, C., Aubert, N., Bernard, J., Lemonnier, F., Raposo, G., Escudier, B., Hsu, D.-H., Tursz, T., Amigorena, S., Angevin, E., Zitvogel, L., Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 172:4 (2004), 2126–2136.
168. [168] Chaput, N., Schartz, N.E.C., André, F., Taïeb, J., Novault, S., Bonnaventure, P., Aubert, N., Bernard, J., Lemonnier, F., Merad, M., Adema, G., Adams, M., Ferrantini, M., Carpentier, A.F., Escudier, B., Tursz, T., Angevin, E., Zitvogel, L., Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol. 172:4 (2004), 2137–2146.
169. [169] Beauvillain, C., Ruiz, S., Guiton, R., Bout, D., Dimier-Poisson, I., A vaccine based on exosomes secreted by a dendritic cell line confers protection against T. gondii infection in syngeneic and allogeneic mice. Microb. Infect. 9:14–15 (2007), 1614–1622.
170. [170] Hsu, D.-H., Paz, P., Villaflor, G., Rivas, A., Mehta-Damani, A., Angevin, E., Zitvogel, L., Le Pecq, J.-B., Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J. Immunother. 26:5 (2003), 440–450.
171. [171] Yin, W., Ouyang, S., Li, Y., Xiao, B., Yang, H., Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity. Inflammation 36:1 (2013), 232–240.
172. [172] Yang, X., Meng, S., Jiang, H., Zhu, C., Wu, W., Exosomes derived from immature bone marrow dendritic cells induce tolerogenicity of intestinal transplantation in rats. J. Surg. Res. 171:2 (2011), 826–832.
173. [173] Kim, S.-H., Lechman, E.R., Bianco, N., Menon, R., Keravala, A., Nash, J., Mi, Z., Watkins, S.C., Gambotto, A., Robbins, P.D., Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J. Immunol. 174:10 (2005), 6440–6448.
174. [174] Cai, Z., Zhang, W., Yang, F., Yu, L., Yu, Z., Pan, J., Wang, L., Cao, X., Wang, J., Immunosuppressive exosomes from TGF-β1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res. 22:3 (2012), 607–610.
175. [175] Kim, S.H., Bianco, N.R., Shufesky, W.J., Morelli, A.E., Robbins, P.D., Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J. Immunol. 179:4 (2007), 2242–2249.
176. [176] Acevedo, R., Fernández, S., Zayas, C., Acosta, A., Sarmiento, M.E., Ferro, V.A., Rosenqvist, E., Campa, C., Cardoso, D., Garcia, L., Perez, J.L., Bacterial outer membrane vesicles and vaccine applications. Front. Immunol., 5, 2014, 121.
177. [177] Price, N.L., Goyette-Desjardins, G., Nothaft, H., Valguarnera, E., Szymanski, C.M., Segura, M., Feldman, M.F., Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines. Sci. Rep., 6, 2016, 24931.
178. [178] Kaparakis-Liaskos, M., Ferrero, R.L., Immune modulation by bacterial outer membrane vesicles. Nat. Rev. Immunol. 15:6 (2015), 375–387.
179. [179] van der Pol, L., Stork, M., van der Ley, P., Outer membrane vesicles as platform vaccine technology. Biotechnol. J. 10:11 (2015), 1689–1706.
180. [180] Collins, B.S., Gram-negative outer membrane vesicles in vaccine development. Discov. Med. 12:62 (2011), 7–15.
181. [181] Holst, J., Oster, P., Arnold, R., Tatley, M.V., Næss, L.M., Aaberge, I.S., Galloway, Y., McNicholas, A., O'Hallahan, J., Rosenqvist, E., Black, S., Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum. Vaccin. Immunother. 9:6 (2013), 1241–1253.
182. [182] Bjune, G., Høiby, E.A., Grønnesby, J.K., Arnesen, O., Fredriksen, J.H., Halstensen, A., Holten, E., Lindbak, A.K., Nøkleby, H., Rosenqvist, E., Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:8775 (1991), 1093–1096.
183. [183] Koeberling, O., Welsch, J.A., Granoff, D.M., Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine 25:10 (2007), 1912–1920.
184. [184] Sanders, H., Norheim, G., Chan, H., Dold, C., Vipond, C., Derrick, J.P., Pollard, A.J., Maiden, M.C.J., Feavers, I.M., FetA antibodies induced by an outer membrane vesicle vaccine derived from a serogroup B meningococcal isolate with constitutive FetA expression. PLoS One, 10(10), 2015, e0140345.
185. [185] Koeberling, O., Seubert, A., Granoff, D.M., Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J. Infect. Dis. 198:2 (2008), 262–270.
186. [186] Koeberling, O., Seubert, A., Santos, G., Colaprico, A., Ugozzoli, M., Donnelly, J., Granoff, D.M., Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29:29–30 (2011), 4728–4734.
187. [187] Schild, S., Nelson, E.J., Bishop, A.L., Camilli, A., Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect. Immun. 77:1 (2009), 472–484.
188. [188] Schild, S., Nelson, E.J., Camilli, A., Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect. Immun. 76:10 (2008), 4554–4563.
189. [189] Raeven, R.H.M., van der Maas, L., Tilstra, W., Uittenbogaard, J.P., Bindels, T.H.E., Kuipers, B., van der Ark, A., Pennings, J.L.A., van Riet, E., Jiskoot, W., Kersten, G.F.A., Metz, B., Immunoproteomic profiling of Bordetella pertussis outer membrane vesicle vaccine reveals broad and balanced humoral immunogenicity. J. Proteom. Res. 14:7 (2015), 2929–2942.
190. [190] McCaig, W.D., Loving, C.L., Hughes, H.R., Brockmeier, S.L., Characterization and vaccine potential of outer membrane vesicles produced by Haemophilus parasuis. PLoS One, 11(3), 2016, e0149132.
191. [191] Nieves, W., Asakrah, S., Qazi, O., Brown, K.A., Kurtz, J., Aucoin, D.P., McLachlan, J.B., Roy, C.J., Morici, L.A., A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 29:46 (2011), 8381–8389.
192. [192] Bartolini, E., Ianni, E., Frigimelica, E., Petracca, R., Galli, G., Berlanda Scorza, F., Norais, N., Laera, D., Giusti, F., Pierleoni, A., Donati, M., Cevenini, R., Finco, O., Grandi, G., Grifantini, R., Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro. J. Extracell. Vesicles, 2, 2013, 20181.
193. [193] Pritsch, M., Ben-Khaled, N., Chaloupka, M., Kobold, S., Berens-Riha, N., Peter, A., Liegl, G., Schubert, S., Hoelscher, M., Löscher, T., Wieser, A., Comparison of intranasal outer membrane vesicles with cholera toxin and injected MF59C.1 as adjuvants for malaria transmission blocking antigens AnAPN1 and Pfs48/45. J. Immunol. Res., 2016, 2016, 3576028.
194. [194] Reza Aghasadeghi, M., Sharifat Salmani, A., Mehdi Sadat, S., Javadi, F., Memarnejadian, A., Vahabpour, R., Zabihollahi, R., Moshiri, A., Davar Siadat, S., Application of outer membrane vesicle of Neisseria meningitidis serogroup B as a new adjuvant to induce strongly Th1-oriented responses against HIV-1. Curr. HIV Res. 9:8 (2011), 630–635.
195. [195] Kim, O.Y., Choi, S.J., Jang, S.C., Park, K.-S., Kim, S.R., Choi, J.P., Lim, J.H., Lee, S.-W., Park, J., Di Vizio, D., Lötvall, J., Kim, Y.-K., Gho, Y.S., Bacterial protoplast-derived nanovesicles as vaccine delivery system against bacterial infection. Nano Lett. 15:1 (2015), 266–274.
196. [196] Wasilewski, T., Gębicki, J., Kamysz, W., Bioelectronic nose: current status and perspectives. Biosens. Bioelectron. 87 (2017), 480–494.
197. [197] Lee, S.H., Park, T.H., Recent advances in the development of bioelectronic nose. Biotechnol. Bioprocess Eng. 15:1 (2010), 22–29.
198. [198] Oh, E.H., Song, H.S., Park, T.H., Recent advances in electronic and bioelectronic noses and their biomedical applications. Enzyme Microb. Technol. 48:6–7 (2011), 427–437.
199. [199] Park, J., Lim, J.H., Jin, H.J., Namgung, S., Lee, S.H., Park, T.H., Hong, S., A bioelectronic sensor based on canine olfactory nanovesicle–carbon nanotube hybrid structures for the fast assessment of food quality. Analyst 137:14 (2012), 3249–3254.
200. [200] Song, H.S., Jin, H.J., Ahn, S.R., Kim, D., Lee, S.H., Kim, U.-K., Simons, C.T., Hong, S., Park, T.H., Bioelectronic tongue using heterodimeric human taste receptor for the discrimination of sweeteners with human-like performance. ACS Nano 8:10 (2014), 9781–9789.
201. [201] Ahn, S.R., An, J.H., Song, H.S., Park, J.W., Lee, S.H., Kim, J.H., Jang, J., Park, T.H., Duplex bioelectronic tongue for sensing umami and sweet tastes based on human taste receptor nanovesicles. ACS Nano 10:8 (2016), 7287–7296.
202. [202] Jin, H.J., Lee, S.H., Kim, T.H., Park, J., Song, H.S., Park, T.H., Hong, S., Nanovesicle-based bioelectronic nose platform mimicking human olfactory signal transduction. Biosens. Bioelectron. 35:1 (2012), 335–341.
203. [203] Lim, J.H., Park, J., Oh, E.H., Ko, H.J., Hong, S., Park, T.H., Nanovesicle-based bioelectronic nose for the diagnosis of lung cancer from human blood. Adv. Healthc. Mater. 3:3 (2014), 360–366.
204. [204] Park, S.J., Song, H.S., Kwon, O.S., Chung, J.H., Lee, S.H., An, J.H., Ahn, S.R., Lee, J.E., Yoon, H., Park, T.H., Jang, J., Human dopamine receptor nanovesicles for gate-potential modulators in high-performance field-effect transistor biosensors. Sci. Rep., 4, 2014, 4342.
205. [205] Ahn, J.H., Lim, J.H., Park, J., Oh, E.H., Son, M., Hong, S., Park, T.H., Screening of target-specific olfactory receptor and development of olfactory biosensor for the assessment of fungal contamination in grain. Sens. Actuators B Chem. 210 (2015), 9–16.
206. [206] Hu, C.-M.J., Zhang, L., Aryal, S., Cheung, C., Fang, R.H., Zhang, L., Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U. S. A 108:27 (2011), 10980–10985.
207. [207] Hu, C.-M.J., Fang, R.H., Luk, B.T., Chen, K.N.H., Carpenter, C., Gao, W., Zhang, K., Zhang, L., “Marker-of-self” functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale 5:7 (2013), 2664–2668.
208. [208] Luk, B.T., Hu, C.-M.J., Fang, R.H., Dehaini, D., Carpenter, C., Gao, W., Zhang, L., Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 6:5 (2014), 2730–2737.
209. [209] Fan, Z., Zhou, H., Li, P.Y., Speer, J.E., Cheng, H., Structural elucidation of cell membrane-derived nanoparticles using molecular probes. J. Mater. Chem. B Mater. Biol. Med. 2:46 (2014), 8231–8238.
210. [210] Gao, W., Hu, C.-M.J., Fang, R.H., Luk, B.T., Su, J., Zhang, L., Surface functionalization of gold nanoparticles with red blood cell membranes. Adv. Mater. 25:26 (2013), 3549–3553.
211. [211] Zhang, J., Gao, W., Fang, R.H., Dong, A., Zhang, L., Synthesis of nanogels via cell membrane-templated polymerization. Small 11:34 (2015), 4309–4313.
212. [212] Fu, Q., Lv, P., Chen, Z., Ni, D., Zhang, L., Yue, H., Yue, Z., Wei, W., Ma, G., Programmed co-delivery of paclitaxel and doxorubicin boosted by camouflaging with erythrocyte membrane. Nanoscale 7:9 (2015), 4020–4030.
213. [213] Kroll, A., Fang, R.H., Zhang, L., Biointerfacing and applications of cell membrane-coated nanoparticles. Bioconjug. Chem. 28:1 (2016), 23–32.
214. [214] Aryal, S., Hu, C.-M.J., Fang, R.H., Dehaini, D., Carpenter, C., Zhang, D.-E., Zhang, L., Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. Nanomed. (Lond.) 8:8 (2013), 1271–1280.
215. [215] Luk, B.T., Fang, R.H., Hu, C.-M.J., Copp, J.A., Thamphiwatana, S., Dehaini, D., Gao, W., Zhang, K., Li, S., Zhang, L., Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics 6:7 (2016), 1004–1011.
216. [216] Fang, R.H., Hu, C.-M.J., Chen, K.N.H., Luk, B.T., Carpenter, C.W., Gao, W., Li, S., Zhang, D.-E., Lu, W., Zhang, L., Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 5:19 (2013), 8884–8888.
217. [217] Su, J., Sun, H., Meng, Q., Yin, Q., Tang, S., Zhang, P., Chen, Y., Zhang, Z., Yu, H., Li, Y., Long circulation red-blood-cell-mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer. Adv. Funct. Mater. 26:8 (2016), 1243–1252.
218. [218] Sun, H., Su, J., Meng, Q., Yin, Q., Chen, L., Gu, W., Zhang, Z., Yu, H., Zhang, P., Wang, S., Li, Y., Cancer cell membrane-coated gold nanocages with hyperthermia-triggered drug release and homotypic target inhibit growth and metastasis of breast cancer. Adv. Funct. Mater., 27(3), 2016, 1604300.
219. [219] Zhu, J.-Y., Zheng, D.-W., Zhang, M.-K., Yu, W.-Y., Qiu, W.-X., Hu, J.-J., Feng, J., Zhang, X.-Z., Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett. 16:9 (2016), 5895–5901.
220. [220] Rao, L., Meng, Q.-F., Huang, Q., Liu, P., Bu, L.-L., Kondamareddy, K.K., Guo, S.-S., Liu, W., Zhao, X.-Z., Photocatalytic degradation of cell membrane coatings for controlled drug release. Adv. Healthc. Mater. 5:12 (2016), 1420–1427.
221. [221] Su, J., Sun, H., Meng, Q., Yin, Q., Zhang, P., Zhang, Z., Yu, H., Li, Y., Bioinspired nanoparticles with NIR-controlled drug release for synergetic chemophotothermal therapy of metastatic breast cancer. Adv. Funct. Mater. 26:41 (2016), 7495–7506.
222. [222] Rao, L., Bu, L.-L., Xu, J.-H., Cai, B., Yu, G.-T., Yu, X., He, Z., Huang, Q., Li, A., Guo, S.-S., Zhang, W.-F., Liu, W., Sun, Z.-J., Wang, H., Wang, T.-H., Zhao, X.-Z., Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small 11:46 (2015), 6225–6236.
223. [223] Fang, R.H., Hu, C.-M.J., Luk, B.T., Gao, W., Copp, J.A., Tai, Y., O'Connor, D.E., Zhang, L., Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 14:4 (2014), 2181–2188.
224. [224] Sun, H., Su, J., Meng, Q., Yin, Q., Chen, L., Gu, W., Zhang, P., Zhang, Z., Yu, H., Wang, S., Li, Y., Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv. Mater. 28:43 (2016), 9581–9588.
225. [225] Parodi, A., Quattrocchi, N., van de Ven, A.L., Chiappini, C., Evangelopoulos, M., Martinez, J.O., Brown, B.S., Khaled, S.Z., Yazdi, I.K., Enzo, M.V., Isenhart, L., Ferrari, M., Tasciotti, E., Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8:1 (2013), 61–68.
226. [226] Krishnamurthy, S., Gnanasammandhan, M.K., Xie, C., Huang, K., Cui, M.Y., Chan, J.M., Monocyte cell membrane-derived nanoghosts for targeted cancer therapy. Nanoscale 8:13 (2016), 6981–6985.
227. [227] Xuan, M., Shao, J., Dai, L., He, Q., Li, J., Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv. Healthc. Mater. 4:11 (2015), 1645–1652.
228. [228] Gao, C., Lin, Z., Jurado-Sánchez, B., Lin, X., Wu, Z., He, Q., Stem cell membrane-coated nanogels for highly efficient in vivo tumor targeted drug delivery. Small 12:30 (2016), 4056–4062.
229. [229] Hu, C.-M.J., Fang, R.H., Wang, K.-C., Luk, B.T., Thamphiwatana, S., Dehaini, D., Nguyen, P., Angsantikul, P., Wen, C.H., Kroll, A.V., Carpenter, C., Ramesh, M., Qu, V., Patel, S.H., Zhu, J., Shi, W., Hofman, F.M., Chen, T.C., Gao, W., Zhang, K., Chien, S., Zhang, L., Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526:7571 (2015), 118–121.
230. [230] Hu, Q., Sun, W., Qian, C., Wang, C., Bomba, H.N., Gu, Z., Anticancer platelet-mimicking nanovehicles. Adv. Mater. 27:44 (2015), 7043–7050.
231. [231] Hu, Q., Qian, C., Sun, W., Wang, J., Chen, Z., Bomba, H.N., Xin, H., Shen, Q., Gu, Z., Engineered nanoplatelets for enhanced treatment of multiple myeloma and thrombus. Adv. Mater. 28:43 (2016), 9573–9580.
232. [232] Silva, A.K.A., Di Corato, R., Pellegrino, T., Chat, S., Pugliese, G., Luciani, N., Gazeau, F., Wilhelm, C., Cell-derived vesicles as a bioplatform for the encapsulation of theranostic nanomaterials. Nanoscale 5:23 (2013), 11374–11384.
233. [233] Lai, P.-Y., Huang, R.-Y., Lin, S.-Y., Lin, Y.-H., Chang, C.-W., Biomimetic stem cell membrane-camouflaged iron oxide nanoparticles for theranostic applications. RSC Adv. 5:119 (2015), 98222–98230.
234. [234] Ren, X., Zheng, R., Fang, X., Wang, X., Zhang, X., Yang, W., Sha, X., Red blood cell membrane camouflaged magnetic nanoclusters for imaging-guided photothermal therapy. Biomaterials 92 (2016), 13–24.
235. [235] Rao, L., He, Z., Meng, Q.-F., Zhou, Z., Bu, L.-L., Guo, S.-S., Liu, W., Zhao, X.-Z., Effective cancer targeting and imaging using macrophage membrane-camouflaged upconversion nanoparticles. J. Biomed. Mater. Res. A 105:2 (2017), 521–530.
236. [236] Rao, L., Bu, L.-L., Cai, B., Xu, J.-H., Li, A., Zhang, W.-F., Sun, Z.-J., Guo, S.-S., Liu, W., Wang, T.-H., Zhao, X.-Z., Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor imaging. Adv. Mater. 28:18 (2016), 3460–3466.
237. [237] Chen, Z., Zhao, P., Luo, Z., Zheng, M., Tian, H., Gong, P., Gao, G., Pan, H., Liu, L., Ma, A., Cui, H., Ma, Y., Cai, L., Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano 10:11 (2016), 10049–10057.
238. [238] Piao, J.-G., Wang, L., Gao, F., You, Y.-Z., Xiong, Y., Yang, L., Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano 8:10 (2014), 10414–10425.
239. [239] Xuan, M., Shao, J., Dai, L., Li, J., He, Q., Macrophage cell membrane camouflaged Au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl. Mater. Interfaces 8:15 (2016), 9610–9618.
240. [240] Ding, H., Lv, Y., Ni, D., Wang, J., Tian, Z., Wei, W., Ma, G., Erythrocyte membrane-coated NIR-triggered biomimetic nanovectors with programmed delivery for photodynamic therapy of cancer. Nanoscale 7:21 (2015), 9806–9815.
241. [241] Gao, C., Lin, Z., Wu, Z., Lin, X., He, Q., Stem-cell-membrane camouflaging on near-infrared photoactivated upconversion nanoarchitectures for in vivo remote-controlled photodynamic therapy. ACS Appl. Mater. Interfaces 8:50 (2016), 34252–34260.
242. [242] Cheng, H., Zhu, J.-Y., Li, S.-Y., Zeng, J.-Y., Lei, Q., Chen, K.-W., Zhang, C., Zhang, X.-Z., An O2 self-sufficient biomimetic nanoplatform for highly specific and efficient photodynamic therapy. Adv. Funct. Mater. 26:43 (2016), 7847–7860.
243. [243] Hu, C.-M.J., Fang, R.H., Copp, J., Luk, B.T., Zhang, L., A biomimetic nanosponge that absorbs pore-forming toxins. Nat. Nanotechnol. 8:5 (2013), 336–340.
244. [244] Wang, F., Gao, W., Thamphiwatana, S., Luk, B.T., Angsantikul, P., Zhang, Q., Hu, C.-M.J., Fang, R.H., Copp, J.A., Pornpattananangkul, D., Lu, W., Zhang, L., Hydrogel retaining toxin-absorbing nanosponges for local treatment of methicillin-resistant Staphylococcus aureus infection. Adv. Mater. 27:22 (2015), 3437–3443.
245. [245] Chhabria, V., Beeton, S., Development of nanosponges from erythrocyte ghosts for removal of streptolysin-O from mammalian blood. Nanomed. (Lond.) 11:21 (2016), 2797–2807.
246. [246] Wu, Z., Li, T., Gao, W., Xu, T., Jurado-Sánchez, B., Li, J., Gao, W., He, Q., Zhang, L., Wang, J., Cell-membrane-coated synthetic nanomotors for effective biodetoxification. Adv. Funct. Mater. 25:25 (2015), 3881–3887.
247. [247] Copp, J.A., Fang, R.H., Luk, B.T., Hu, C.-M.J., Gao, W., Zhang, K., Zhang, L., Clearance of pathological antibodies using biomimetic nanoparticles. Proc. Natl. Acad. Sci. U. S. A 111:37 (2014), 13481–13486.
248. [248] Wei, X., Gao, J., Fang, R.H., Luk, B.T., Kroll, A.V., Dehaini, D., Zhou, J., Kim, H.W., Gao, W., Lu, W., Zhang, L., Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. Biomaterials 111 (2016), 116–123.
249. [249] Pang, Z., Hu, C.-M.J., Fang, R.H., Luk, B.T., Gao, W., Wang, F., Chuluun, E., Angsantikul, P., Thamphiwatana, S., Lu, W., Jiang, X., Zhang, L., Detoxification of organophosphate poisoning using nanoparticle bioscavengers. ACS Nano 9:6 (2015), 6450–6458.
250. [250] Nguyen, T.D.T., Pitchaimani, A., Koirala, M.B., Muhammad, F., Aryal, S., Engineered biomimetic nanoabsorbent for cellular detoxification of chemotherapeutics. RSC Adv. 6:39 (2016), 33003–33008.
251. [251] Hu, C.-M.J., Fang, R.H., Luk, B.T., Zhang, L., Nanoparticle-detained toxins for safe and effective vaccination. Nat. Nanotechnol. 8:12 (2013), 933–938.
252. [252] Wang, F., Fang, R.H., Luk, B.T., Hu, C.-M.J., Thamphiwatana, S., Dehaini, D., Angsantikul, P., Kroll, A.V., Pang, Z., Gao, W., Lu, W., Zhang, L., Nanoparticle-based antivirulence vaccine for the management of methicillin-resistant Staphylococcus aureus skin infection. Adv. Funct. Mater. 26:10 (2016), 1628–1635.
253. [253] Guo, Y., Wang, D., Song, Q., Wu, T., Zhuang, X., Bao, Y., Kong, M., Qi, Y., Tan, S., Zhang, Z., Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano 9:7 (2015), 6918–6933.
254. [254] Gao, W., Fang, R.H., Thamphiwatana, S., Luk, B.T., Li, J., Angsantikul, P., Zhang, Q., Hu, C.-M.J., Zhang, L., Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett. 15:2 (2015), 1403–1409.
255. [255] Anselmo, A.C., Mitragotri, S., Nanoparticles in the clinic. Bioeng. Transl. Med. 1:1 (2016), 10–29.